Evaluation of nitazoxanide in combination with pegylated interferon and ribavirin in treatment of patients with chronic HCV genotype 4 / Mahmoud Mohammad Magdy Taha ; Supervised Gamal Eldeen Esmat Gameel , Maissa Elsaid Elraziky , Badawy Elkholy
Material type:
- تقييم عقار النيتازوكسانيد فى علاج المرضى المصابين بالتهاب الكبد الفيروسى ج المزمن الطور الجينى الرابع مع الإنترفيرون والريبافيرين [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.33.Ph.D.2012.Ma.E (Browse shelf(Opens below)) | Not for loan | 01010110060146000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.33.Ph.D.2012.Ma.E (Browse shelf(Opens below)) | 60146.CD | Not for loan | 01020110060146000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine
Sustained virologic response (SVR ) rates of 50 % - 60 % have been achieved in patients with chronic hepatitis C (CHC) genotype 4 treated with peginterferon (PEG-IFN) plus ribavirin (RBV) . The safety and efficacy of nitazoxanide (NTZ) plus peginterferon alfa-2a , with ribavirin , were evaluated in a case controlled study at 2 centers in Egypt . This study aims at assessing the safety and efficacy of NTZ in treating Egyptian patients with CHC in combination with PEG-IFN and RBV
Issued also as CD
There are no comments on this title.